AI for MLR Review: What Is Actually Being Automated in Pharma Promotional Content

AI for MLR review is the use of AI to pre-check pharmaceutical promotional materials against approved claims, current labelling and internal policy before they reach medical, legal and regulatory (MLR) reviewers, so that reviewers spend their time on genuine judgement calls rather than routine checks. It does not replace MLR approval; it changes what arrives on the reviewer's desk and how quickly approved content reaches market.

What MLR review is, and why it is a bottleneck

Every piece of pharma promotional content, from a banner ad to a rep detail aid, must be reviewed by medical, legal and regulatory specialists before use. Reviewers confirm that each claim is supported by evidence, consistent with the product label, fairly balanced with safety information and compliant with company policy. In the US, promotional materials fall under FDA oversight through the Office of Prescription Drug Promotion, and companies submit them at first use.

The process is slow for structural reasons:

• Volume keeps rising. Omnichannel marketing means more formats, more versions and more local adaptations of each asset.
• Much of the checking is routine. Matching a claim to its reference, confirming the fair-balance statement is present and checking the latest label version are repetitive but must be done every time.
• Rework loops are common. An asset with a missing reference goes back to the agency, returns, and re-enters the queue.
• Review is only half the journey. After approval, someone still has to set the asset up correctly in media platforms, often by hand.

What AI can and cannot automate in MLR

It helps to split the work into three layers.

Layer 1: mechanical checks (high automation potential)

• Is every claim referenced, and does the reference exist in the approved library?
• Does the claim match the current label wording and indication?
• Are required elements present: fair balance, important safety information, prescribing information link, legal lines?
• Are brand rules followed: product name formatting, trademark symbols, approved imagery?

Layer 2: comparative judgement (assisted automation)

• Is this claim materially the same as one already approved, or a new claim?
• Does the overall impression overstate efficacy or understate risk?
• Is a localised version still consistent with the global master?

AI can flag likely issues here with reasons, but a reviewer should make the call.

Layer 3: approval and accountability (stays human)

• Final sign-off by medical, legal and regulatory reviewers.
• Decisions on novel claims, borderline language and risk tolerance.

The realistic gain comes from automating Layer 1 almost entirely, assisting Layer 2, and leaving Layer 3 to people with a cleaner, pre-checked queue.

Approaches on the market

Content and review platforms with AI features (e.g. Veeva PromoMats)

• Strengths: already the system of record for many pharma MLR teams; AI features sit inside the existing review workflow.
• Consider: the AI typically works within that platform, so steps before and after review, such as agency intake or media set-up, may stay manual.

Agency and services models

• Strengths: experienced people who know MLR expectations; flexible capacity.
• Consider: cost scales with volume, and turnaround depends on staffing.

General-purpose AI tools and copilots

• Strengths: quick to try for drafting or summarising references.
• Consider: no built-in link to approved claims libraries or label versions, and limited audit trail, which matters for regulated content.

Digital Workers

• Strengths: run the workflow end to end, from asset intake through claim checks to campaign set-up, across several systems, with flagged exceptions for reviewers.
• Consider: a newer category; buyers should test accuracy on their own historical assets before relying on it.

How an MLR Digital Worker works, step by step

The causaLens Programmatic Media Digital Worker, shown on the Demo Hub, automates marketing asset intake, medical claim validation and campaign set-up. A typical run looks like this:

1. Intake. A new or revised asset arrives from an agency or internal team.
2. Claim extraction. The worker identifies every claim, reference and required element in the asset.
3. Validation. Each claim is checked against the approved claims library, the current label and brand policy.
4. Exception flagging. Unsupported, changed or missing items are flagged with the reason and the source they were checked against.
5. Human review. MLR reviewers work through the flags and approve, reject or request changes.
6. Campaign set-up. Approved assets are configured in the relevant media platforms, aligned to campaign objectives.
7. Monitoring. Live campaigns are tracked, and performance feeds back to the brand team.

According to the causaLens customer story, a major pharma company used this approach to automate end-to-end creative QA, running 24/7 with human oversight on exceptions.

Proof point

Syneos Health, a fully integrated biopharmaceutical solutions organisation, expanded its partnership with causaLens in May 2026. Its deployed capabilities include digital media campaign execution with ongoing monitoring and optimisation. Stephen Hoelper, Global Head, Commercial Product at Syneos Health, said causaLens Digital Workers provide "insights that have the ability to accelerate launch, adoption and growth for our biopharmaceutical customers."

What to ask before automating MLR pre-review

1. Which approved claims library and label sources will the AI check against, and how are updates picked up?
2. What is the miss rate on a sample of your own previously reviewed assets?
3. Does every flag show the reason and the source it was checked against?
4. How does the output connect to your existing review platform?
5. Who owns updates when guidance, labels or brand rules change?

Related guides

• AI and Digital Workers in pharma: a complete guide
• Digital Workers vs RPA vs copilots

FAQ

Can AI approve pharma promotional materials?

No. Final approval stays with medical, legal and regulatory reviewers. AI pre-checks content and flags issues so reviewers can focus on judgement.

What parts of MLR review can AI automate?

Mechanical checks are the best fit: matching claims to references, comparing wording with the current label, and confirming required safety and legal elements are present.

Does AI MLR pre-review replace Veeva PromoMats?

Not necessarily. Many teams keep their review platform as the system of record and use AI before and after it, for intake checks and campaign set-up.

How do you know the AI's checks are accurate?

Test it on a sample of historical assets with known outcomes, measure what it missed and what it over-flagged, and require every flag to cite its source.

What happens after an asset is approved?

A Digital Worker can configure the approved asset in media platforms and monitor campaign performance, steps that are often still manual.

Is AI MLR review compliant with FDA requirements?

The AI does not change regulatory obligations. Companies remain responsible for promotional content, so the AI should be used with documented processes, audit trails and human sign-off.